A BioNTech resolve disputas de patentes sobre royalties de vacinas COVID-19, pagando US $ 1,26 bilhão para NIH e Penn. BioNTech settles patent disputes over COVID-19 vaccine royalties, paying $1.26B to NIH and Penn.

A BioNTech, co-desenvolvedora da vacina Pfizer COVID-19, resolveu disputas sobre royalties com os Institutos Nacionais de Saúde dos EUA (NIH) e a Universidade da Pensilvânia (Penn). BioNTech, co-developer of the Pfizer COVID-19 vaccine, has settled disputes over royalties with the US National Institutes of Health (NIH) and the University of Pennsylvania (Penn). A BioNTech pagará US$ 791,5 milhões ao NIH e US$ 467 milhões à Penn. BioNTech will pay $791.5 million to NIH and $467 million to Penn. A Pfizer reembolsará a BioNTech até US$ 534,5 milhões desses pagamentos. Pfizer will reimburse BioNTech up to $534.5 million of these payments. Os acordos incluem acordos de licença para uso futuro das patentes envolvidas. The settlements include license agreements for future use of the patents involved.